Cipla’s arm makes additional investment of $3 million in Chase Pharmaceuticals

16 Mar 2016 Evaluate

Cipla’s wholly owned subsidiary - Cipla (EU), UK (Cipla UK), has pursuant to the approval of the board of Cipla UK, made an additional investment of $3 million in Chase Pharmaceuticals Corporation Inc., US (Chase) towards full settlement of its obligation under the agreed arrangement for investment in Chase. Consequently, Cipla UK’s total investment in Chase would aggregate to approximately $5.12 million for a 16.7% stake on a fully diluted basis.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.


Cipla Share Price

1377.85 -13.35 (-0.96%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×